SCHEMBL5842282

SCHEMBL5842282

CCn1c2ccccc2c2cc(NC(=O)C3CC(=O)N(Cc4ccccc4)C3)ccc21

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.64
LMNA P02545 3/20 0.62
HTT P42858 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
MAPT P10636 4/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
NPC1 O15118 2/20 0.62
GLA P06280 1/20 0.62
RAB9A P51151 1/20 0.62
KMT2A Q03164 2/20 0.60
KDM4E B2RXH2 1/20 0.60
HPGD P15428 1/20 0.60
MEN1 O00255 1/20 0.57
PKM P14618 1/20 0.56
NPY5R Q15761 1/20 0.55
NPSR1 Q6W5P4 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5843034 0.94 ALDH1A1 (0.56) ALDH1A1LMNAHTTL3MBTL1MAPT
SCHEMBL5842472 0.91 SMN1; SMN2 (0.61) ALDH1A1LMNAHTTL3MBTL1MAPT
SCHEMBL5841477 0.90 NPSR1 (0.52) ALDH1A1LMNAHTTL3MBTL1MAPT
SCHEMBL5842710 0.87 RORC (0.53) ALDH1A1LMNAL3MBTL1MAPTSMN1; SMN2
SCHEMBL5842037 0.87 MAPT (0.57) ALDH1A1LMNAHTTL3MBTL1MAPT
SCHEMBL5842516 0.87 MAPT (0.65) ALDH1A1LMNAHTTL3MBTL1MAPT
SCHEMBL5842465 0.85 NPSR1 (0.56) ALDH1A1LMNAL3MBTL1MAPTSMN1; SMN2
SCHEMBL6611824 0.84 NPY5R (0.52) ALDH1A1LMNAMAPTSMN1; SMN2NPC1
SCHEMBL5841833 0.83 MAPT (0.53) ALDH1A1LMNAHTTMAPTSMN1; SMN2
SCHEMBL5842084 0.83 NPY5R (0.66) ALDH1A1LMNAHTTL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100534990-C Pyrrolidone carboxamides ACTELION PHARMACEUTICALS LTD (CH) 2009-09-02 CN claimed
US-7067549-B2 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2006-06-27 US claimed
US-20050192292-A1 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2005-09-01 US claimed
CN-1610678-A Pyrrolidone carboxamides ACTELION PHARMACEUTICALS LTD (CH) 2005-04-27 CN claimed
CN-100534990-C Pyrrolidone carboxamides ACTELION PHARMACEUTICALS LTD (CH) 2009-09-02 CN disclosed
US-7067549-B2 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2006-06-27 US disclosed
US-20050192292-A1 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2005-09-01 US disclosed
CN-1610678-A Pyrrolidone carboxamides ACTELION PHARMACEUTICALS LTD (CH) 2005-04-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192292-A1 Pyrrolidone carboxamides NPY1R, NPY5R, NPY2R ALDH1A1 3034/4885LMNA 3430/4885HTT 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.